UBS Group AG - Net Worth and Insider Trading

UBS Group AG Net Worth

The estimated net worth of UBS Group AG is at least $38 Million dollars as of 2024-11-13. UBS Group AG is the 2201 Interest of corporation controlled by you of Lee's Pharmaceutical Holdings Ltd and owns about 29,570,569 shares of Lee's Pharmaceutical Holdings Ltd (HKSE:00950) stock worth over $38 Million. Details can be seen in UBS Group AG's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that UBS Group AG has not made any transactions after 2024-05-08 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of UBS Group AG

To

UBS Group AG Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, UBS Group AG owns 1 companies in total, including Lee's Pharmaceutical Holdings Ltd (HKSE:00950) .

Click here to see the complete history of UBS Group AG’s form 4 insider trades.

Insider Ownership Summary of UBS Group AG

Ticker Comapny Transaction Date Type of Owner
HKSE:00950 Lee's Pharmaceutical Holdings Ltd 2024-05-08 2201 Interest of corporation controlled by you

UBS Group AG Latest Holdings Summary

UBS Group AG currently owns a total of 1 stock. UBS Group AG owns 29,570,569 shares of Lee's Pharmaceutical Holdings Ltd (HKSE:00950) as of May 8, 2024, with a value of $38 Million.

Latest Holdings of UBS Group AG

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
HKSE:00950 Lee's Pharmaceutical Holdings Ltd 2024-05-08 29,570,569 1.28 37,850,328

Holding Weightings of UBS Group AG


UBS Group AG Form 4 Trading Tracker

According to the SEC Form 4 filings, UBS Group AG has made a total of 3 transactions in Lee's Pharmaceutical Holdings Ltd (HKSE:00950) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Lee's Pharmaceutical Holdings Ltd is the sale of 0 shares on May 8, 2024, which brought UBS Group AG around $0.

Insider Trading History of UBS Group AG

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

UBS Group AG Trading Performance

GuruFocus tracks the stock performance after each of UBS Group AG's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by UBS Group AG is -8.82%. GuruFocus also compares UBS Group AG's trading performance to market benchmark return within the same time period. The performance of stocks bought by UBS Group AG within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how UBS Group AG's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of UBS Group AG

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
0 out of 1 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -4.41 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) -6.33 LIMIT LIMIT LIMIT LIMIT LIMIT

UBS Group AG Ownership Network

Ownership Network List of UBS Group AG

No Data

Ownership Network Relation of UBS Group AG

Insider Network Chart

UBS Group AG Owned Company Details

What does Lee's Pharmaceutical Holdings Ltd do?

Who are the key executives at Lee's Pharmaceutical Holdings Ltd?

UBS Group AG is the 2201 Interest of corporation controlled by you of Lee's Pharmaceutical Holdings Ltd. Other key executives at Lee's Pharmaceutical Holdings Ltd include 2101 Beneficial owner Leelalertsuphakun Wanee , 2201 Interest of corporation controlled by you HUANG ZUIE-CHIN , and 2101 Beneficial owner Lee Siu Fong .

Lee's Pharmaceutical Holdings Ltd (HKSE:00950) Insider Trades Summary

Over the past 18 months, UBS Group AG made 3 insider transaction in Lee's Pharmaceutical Holdings Ltd (HKSE:00950) with a net purchase of 500,001. Other recent insider transactions involving Lee's Pharmaceutical Holdings Ltd (HKSE:00950) include a net purchase of 629,000 shares made by Leelalertsuphakun Wanee , a net purchase of 925,000 shares made by Li Xiaoyi , and a net purchase of 925,000 shares made by Lue Shuk Ping Vicky .

In summary, during the past 3 months, insiders sold 0 shares of Lee's Pharmaceutical Holdings Ltd (HKSE:00950) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Lee's Pharmaceutical Holdings Ltd (HKSE:00950) were sold and 35,047,500 shares were bought by its insiders, resulting in a net purchase of 35,047,500 shares.

Lee's Pharmaceutical Holdings Ltd (HKSE:00950)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Lee's Pharmaceutical Holdings Ltd Insider Transactions

No Available Data

UBS Group AG Mailing Address

Above is the net worth, insider trading, and ownership report for UBS Group AG. Currently GuruFocus does not have mailing address information for UBS Group AG.